Integrity Alliance LLC. cut its position in Boston Scientific Corporation (NYSE:BSX – Free Report) by 71.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,258 shares of the medical equipment provider’s stock after selling 13,247 shares during the quarter. Integrity Alliance LLC.’s holdings in Boston Scientific were worth $501,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the company. Egerton Capital UK LLP grew its stake in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after acquiring an additional 3,671,548 shares during the last quarter. Alphinity Investment Management Pty Ltd acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $252,918,000. Marshall Wace LLP increased its holdings in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. Credit Agricole S A acquired a new position in shares of Boston Scientific during the third quarter valued at about $204,812,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Boston Scientific by 28.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 8,367,398 shares of the medical equipment provider’s stock valued at $816,909,000 after acquiring an additional 1,837,480 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.
Insider Activity at Boston Scientific
In other news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 9,800 shares of company stock worth $554,012 over the last quarter. Insiders own 0.34% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Analysis on Boston Scientific
Trending Headlines about Boston Scientific
Here are the key news stories impacting Boston Scientific this week:
- Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
- Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
- Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
- Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
- Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
- Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)
Boston Scientific Price Performance
Shares of NYSE BSX opened at $48.32 on Friday. The business’s 50 day moving average price is $60.23 and its 200 day moving average price is $78.62. The firm has a market cap of $71.82 billion, a P/E ratio of 20.22, a P/E/G ratio of 0.90 and a beta of 0.62. Boston Scientific Corporation has a 52 week low of $48.13 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.37 earnings per share for the current year.
Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
See Also
- Five stocks we like better than Boston Scientific
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
